SMARCB1-deficient Renal Medullary Carcinoma
1 clinical trials · Condition
◉ Watch SMARCB1-deficient Renal Medullary Carcinoma
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma (NCT07438626) | M.D. Anderson Cancer Center | 2026-06-01 |
Track SMARCB1-deficient Renal Medullary Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.